New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 1, # 6 - October, 1995

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
MALIGNANT MELANOMA - PART II
New Drugs and Modalities in Development for the Treatment of Malignant Melanoma 142
Immunotherapy Approaches for the Treatment of Malignant Melanoma 142
  Systematically-delivered Cytokines as Immunomodulators 143
  Systematically-delivered Interferons 143
    Inteferon-alpha 143
    IFN-alpha 2b combined with Melacine 143
    IFN-alpha 2a/retinoid combinations 144
    IFN-gamma 144
  Systematically-delivered Interleukins 144
    Interleukin-2 144
    IL-2 analogs 144
    Cell Therapeutics 144
    IL-2/IFN-alpha combinations 145
    Il-2/IL-1 beta combinations 145
    IL-2.loxoribine combinations 145
    IL-4 145
    IL-12 145
  Active Specific Immunotherapy-Tumor Cell Vaccines 145
    Ribi ImmunoChem Research 147
    Lidak Pharmaceuticals 147
    Cytel 147
    StressGen Biotechnologies 147
  Active Specific Immunotherapy-Gene Transfer 148
    Immunex 149
    Somatix Therapy 149
    Targeted Genetics 149
    Boehringer Ingelheim 149
    RGene Therapeutics 149
    Genetic Therapy 149
    Vical 150
    Therion Biologics 150
  Active Specific Immunotherapy-Monoclonal Antibodies 150
    ImClone Systems 150
  Adoptive Immunotherapy 150
    Cellcor 151
  Passive Immunotherapy 151
  Gene Transfer-HSV Thymidine Kinase Gene 150
    Pasteur Institute 152
    Genopoietic 152
Other Agents in Development 152
  Dovetail Technologies 152
  Melatonin 152
  Melanoma Inhibitory Activity (MIA) Protein 152
  SunPharm 152
  Cancer Research Campaign Technology 152
Isolated Limb Perfusion 158
MEETING COVERAGE
OPPORTUNISTIC INFECTIONS IN CANCER PATIENTS
A Report From the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
San Francisco, CA - September 17-20, 1995
Bacterial Infections 159
  Enterococcus faecium (VREF) 159
  Viridians Streptococcal Bacteremia 160
  New Therapeutic Modalities for Opportunistic Bacterial Infections 160
    Meropenem 160
    Combination of Ciprofloxacin and Piperacillin 160
Viral Infections 160
  Cytomegalovirus (CMV) 160
  New Therapeutic Modalities for Opportunistic Viral Infections 161
    Low-dose intravenous acyclovir 161
    Varicella zoster immune globulin prophylaxis 161
Fungal Infections 161
  Pneumocystis carinii Pneumonia 162
  New Therpeutic Modalities for Opportunistic Fungal Infections 163
    Itraconazole in invasive pulmonary aspergillosis 163
    Amphotericin B lipid complex 163
    Liposomal nystatin 163
Bloodstream Infections 164
TECHNOLOGY UPDATE
NUCLEAR MEDICINE
Unique Applications of Nuclear Medicine Are Expanding in Oncology 164
Pet/Spect and High Energy Imaging 164
  FDG Imaging Based on Cellular Metabolism 164
    Evaluation of solitary pulmonary nodules in lung cancer 165
    Whole-body nuclear imaging 165
    Determination of lung cancer that has spread to the mediastinum 165
    Differentiation between malignant and benign breast tumors 165
Scinti-Mammography and Evaluation of Tumors in the Dense Breast 165
Detection of Tumors Exhibiting Multidrug Resistance 166
Radiolabeled Somatostatin for Selectively Targeting Disease 166
  Indium-labeled Somatostatin 167
    Mallinckrodt Medical 167
    CIS-US 167
  Technetium-labeled Peptides 167
    Diatech 167
  Radiotracers that Bind to Other Somatostatin Receptor Subtypes 167

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887